Key result
Adenosine inhibits human but not rat platelet aggregation due to its inability to sufficiently increase cAMP in rat platelets, acting both as an inhibitor via adenylate cyclase and a potentiator via uptake.
Why the study?
Does adenosine inhibit platelet aggregation through cAMP elevation differently in human versus rat platelets?
Population
Human and rat platelets
Comparison
Adenosine, prostaglandin E1 (PGE1), or RA233 vs Control values or comparative concentrations of…
Design
Preclinical
Authors
Loading...
Rat models may underestimate adenosine's antiplatelet effects in humans; leaves open species-specific cAMP mechanisms for targeted research.
Does adenosine inhibit platelet aggregation through cAMP elevation differently in human versus rat platelets?
The comparative ineffectiveness of adenosine as an inhibitor of rat platelet aggregation is due to its inability to sufficiently increase cAMP, alongside a potentiating effect via cellular uptake.
Michel et al. (1976) studied this question. Adenosine, PGE1, and RA233 vs. Control was evaluated on Platelet aggregation and cAMP concentration. Adenosine inhibits human but not rat platelet aggregation due to its inability to sufficiently increase cAMP in rat platelets, acting both as an inhibitor via adenylate cyclase and a potentiator via uptake.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: